june 14, 2011

cancer center update


News briefs

Xavier Llor published in JAMA
An editorial by Xavier Llor, MD, PhD, on cancer risk assessment in Lynch Syndrome appears in the current issue of the Journal of the American Medical Association. To see the full editorial, click here.

Rick Kittles to Co-Chair Disparities Conference.
Rick Kittles, PhD,
is Co-Chair of the American Association for Cancer Research's “The Science of Cancer Health Disparities” Conference. Click here for more information about the conference, which will be held in September in Washington, DC.

New members
The Cancer Center is pleased to welcome these two members to its Cancer Targeting, Therapeutics, and Imaging Program:

Herbert Engelhard, MD, PhD, FACS, is Associate Professor in the Department of Neurosurgery in the College of Medicine. His cancer research interest is the development of new cancer treatments, especially for patients with malignant brain tumors.

Engelhard has been one of four U.S. doctors overseeing the ongoing clinical studies of the NovoTTF device that has just received FDA approval. He became involved in the testing of the device because he had done a previous study with the manufacturer (NovoCure). That was over four years ago, and the UI Medical Center subsequetly became the first hospital in the U.S. to treat patients with glioblastoma using the NovoTTF. 23 patients participated in the study.

According to Engelhard, although it has been approved, the methods is not widely available yet. "The manufacturer is working with insurers now," he explained. To see the original article, click here.

Brian T. Murphy PhD, is Assistant Professor of Medicinal Chemistry and Pharmacognosy in the College of Pharmacy. His cancer interest lies in the discovery of cancer therapeutics from marine actinomycetes.


Shared Resource Focus: Protocol Review and Monitoring Committee

The Cancer Center’s Protocol Review and Monitoring Committee (PRMC) is another of the many valuable Shared Resources that benefit Cancer Center members.
The purpose of the PRMC is to provide internal, centralized oversight of scientific aspects of cancer clinical research under the auspices of the Cancer Center. All new cancer-related protocols must receive committee approval prior to activation. Subject enrollment cannot begin until protocols have been approved by both the PRMC and UIC’s Institutional Review Board.

The PRMC of 13 full members is of sufficient size and breadth to allow a critical and fair review of all cancer research protocols. PRMC membership is multidisciplinary with a constituency that is broadly representative of the basic and clinical scientific disciplines across specialty areas including: behavioral health science, hematology, medical oncology, surgical oncology, epidemiology, pathology, and pharmacy. Ad hocmembers are used when needed.  

Scientific leadership is provided by the Chair of the PRMC, Robert Molokie, MD, who is Assistant Professor in the Section of Hematology/Oncology and Medical Director of the UIC Adult Sickle Cell Center Program. Cancer Center administrative leadership is provided by Regina Schwind, PRMC Coordinator.

The primary aim of the PMRC is to verify the protocol’s scientific merit, including the use of appropriate research methods and statistical analysis. This constructive critique helps the Principal Investigator fine-tune the proposed protocol to ensure it contains all elements necessary for the proper conduct of clinical research.  PRMC review has a particular emphasis on: the scientific merit of the protocol; feasibility of local study conduct with regard to research support and resources; and prioritization of the protocol within the Cancer Center’s portfolio of clinical research. Even though it is mandatory, this review is intended to assist investigators in the development of their protocols by providing scientific expertise, which can help facilitate more rapid protocol activation.

The PRMC is responsible for:

  • Conducting a full scientific review of all new institutionally sponsored and investigator-initiated non-peer reviewed clinical research
  • Conducting feasibility studies of new and continuing peer-reviewed protocols
  • Assisting Principal Investigators in resubmission based on written reviews and feedback
  • Prioritizing competing protocols
  • Monitoring protocols for sufficient progress, including adequate rates of participant accrual
  • Terminating protocols that do not meet scientific and accrual goals
  • Reviewing and recommending changes to PRMC policies and procedures

All protocols are assigned to a primary reviewer and, where necessary, a biostatistician or secondary reviewer, for review.
New protocols are evaluated according to these criteria: 

  • Clarity of presentation
  • Rationale
  • Research objectives
  • Eligibility and study requirements
  • Treatment or study plan

Continuing protocols are reviewed for:

  • Accrual
  • Toxicity
  • Adherence to regulatory guidelines and protocol
  • Prioritization
  • Continued scientific merit

After review, the protocol is either approved; approved with modifications; deferred due to overlap; deferred due to scientific reason; disapproved (for new protocols) or terminated (for continuing protocols). The PRMC has the authority to terminate protocols which do not satisfy the specified criteria.  The review outcome is communicated to the PI and research coordinator  no later than three business days following a meeting. Scientifically deferred protocols may be submitted for re-review via the current appeal process.

To submit either new or continuing protocols, please complete the corresponding submission forms for the appropriate protocol. Further details about protocol reviews and decisions can be found by reviewing the Procedures and Policies.

Important note: When a researcher receives IRB notification that a continuing review report is due, the UIC IRB Continuing Review of Research Form and the CC-PRC Continuing Review Submission Form should be completed.  The protocol can be submitted to both the PRC and UIC IRB simultaneously.

The meetings of the PRMC are held twice monthly on Thursdays and protocol submissions are due approximately two weeks before each meeting date. Click here for the 2011 PRMC Schedule.



return to top


In this issue
  Shared resource focus: Protocol Review
and Monitoring committee
  upcoming events
  recent publications
  New funding opportunities


Cancer Center participates in American Cancer Society-Illinois Summer High School Research Program

The Cancer Center has a close and robust relationship with the Illinois Division of the American Cancer Society (ACS). This partnership was evident on Saturday, June 4th, last weekend when we hosted  a breakfast honoring the recipients of the ACS's Summer High School Research Program.

Over 90 students and their parents attended.   Adrienne White, Vice President of Health Initiatives and Advocacy for the ACS-Illinois, welcomed the group and presented a short overview on cancer and the research process.

Established in 2003, the program gives talented students the opportunity to work with leading cancer researchers whose mentorship guides their research  experience. It is very effective in helping students explore academic and career options in public health, science and medicine. Elizabeth Jablonski, PhD, Director of Research, Health Initiatives and Advocacy for the ACS-Illinois, explains the benefits to students: "It's a fantastic opportunity for high school students   to find out what it means to be a scientist." The experience is valuable for mentors also.  Jablonski continues: "Anytime you are in a position to teach someone else what you are doing, it gives you a new perspective."

We are also proud that two of our Cancer Center members will be mentoring students this summer, as many members have in past years. Charlotte Joslin, OD, PhD, and Faith G. Davis, PhD, have generously offered to be mentors. Both are members of the Cancer Control and Population Science Program.

Many other persons are providing support for the program. According to Faith Davis: "Cancer Center member Angela Odoms-Young, PhD, MS, is providing a practical community data collection experience." Davis added that there are many pre-docs and post-docs helping with various aspects of the program.


Upcoming events
Anti-Angiogenesis Therapy: Past, Present, Future
Debabrata Mukhopadhyay, PhD, Mayo Clinic. 
Thursday, June 16, 2011
COMRB (Note different location.)
909 S. Wolcott, Rm. 5175

Presented by the Cancer Cell Signaling Program.

recent publications

Genome-wide Association Study of Prostate Cancer in Men of African Ancestry Identifies a Susceptibility Locus at 17q21  
Rick Kittles, PhD, et al

National Cancer Institute Prostate Cancer Genetics Workshop
Rick Kittles, PhD, et al

Novel Regulation of Nuclear Factor-YB by miR-485-3p Affects the Expression of DNA Topoisomerase IIα and Drug Responsiveness
W.T. Beck, PhD, et al

EphB2 SNPs and Sporadic Prostate Cancer Risk in African American Men
Rick Kittles, PhD, et al

Telomere Dysfunction Promotes Metastasis in a Terc Null Mouse Model of Head and Neck Cancer
David Crowe, PhD, et  al

Postdischarge Venous Thromboembolism after Cancer Surgery: Extending the Case for Extended Prophylaxis
Howard Gordon, MD, et al

Nonredundant Functions for Akt Isoforms in Astrocyte Growth and Gliomagenesis in an Orthotopic Transplantation Model
Nissam Hay, PhD, et al

FoxM1 in Tumorigenicity of the Neuroblastoma Cells and Renewal of the Neural Progenitors
Angela Tyner, PhD, Srilata Bagchi, PhD, Pradip Raychaudhuri, PhD, et al

Estrogen-initiated Transformation of Prostate Epithelium derived from Normal Human Prostate Stem-Progenitor Cells
Andre Kajdacsy Balla, MD, PhD, Gail Prins, PhD, et al

Nephroblastoma Overexpressed (NOV/CCN3) Gene: A Paired-Domain-Specific PAX3-FKHR Transcription Target that Promotes Survival and Motility in Alveolar Rhabdomyosarcoma Cells
Chiayeng Wang, PhD, et al

Hematologic Adverse Events Associated with Temozolomide John Villano, MD, PhD, et al

Assessment of Oral Toxicity and Safety of 9-cis-UAB30, a PotentialChemopreventive Agent, in Rat and Dog Studies
Aleksander Lyubimov, MD, PhD, et al

new funding opportunities

Cancer Prevention Fellowship Program
National Cancer Institute
Deadline: Online App Aug. 25, 2011; Supporting Docs Aug. 31, 2011

Support for postdoctoral training opportunities in cancer prevention and control to train individuals from various disciplines in the field of cancer prevention and control.

Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) - PAR-08-020
National Cancer Institute
Deadline: LOI August 21, 2010; App Sept 20, 2011

Inviting new or renewal (competing) applications for P50 Research Center Specialized Programs of Research Excellence (SPOREs) to support state-of-the-art investigator-initiated research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer.

Biology of Manual Therapies (R01)
National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI)
Deadline: App Sept. 25, 2011

Seeking research grant applications (R01) from institutions/organizations that propose to investigate the basic science and mechanisms of action underlying the biomechanical, immunological, endocrinological and/or neurophysiological consequences of manual therapies, such as spinal manipulation, mobilization and massage therapy

Biology of Manual Therapies (R21)
National Center for Complementary and Alternative Medicine (NCCAM) and National Cancer Institute (NCI)
Deadline: App Sept. 25, 2011

Seeks research grant applications (R21) from institutions that propose to investigate the basic science and mechanisms of action underlying the biomechanical, immunological, endocrinological and/or neurophysiological consequences of manual therapies, such as spinal manipulation, mobilization and massage therapy.

ASH Abstract Achievement Awards
American Society of Hematology (ASH)
Deadline: App Aug. 12, 2011

To help defray annual meeting travel costs for abstract presenters who demonstrate a need for financial assistance.

ASH Outstanding Abstract Achievement Awards and Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
American Society of Hematology (ASH)
Deadline: App Aug. 12, 2011

For trainee who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis.

AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research
American Association for Cancer Research (AACR)
Deadline: Letter of nomination June 13, 2011

For a  seminal contribution to the field of cancer prevention. Such investigations must have been conducted in basic, translational, clinical, epidemiological, or behavioral science in cancer prevention research.  

Community Clinical Oncology Program Research Bases (U10)
National Cancer Institute
Deadline: LOI June 28, 2011; App July 28, 2011

Support for Research Bases for the NCI-supported Community Clinical Oncology Program (CCOP) Network to develop and conduct state-of-the-art cancer prevention, control, and treatment clinical trials with significant involvement of community oncologists and populations they serve.  

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)
National Cancer Institute
Deadline:App July 27, 2011, Nov. 10, 2011, Mar. 13, 2012

For clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools.  

Community Clinical Oncology Program Groups (U10)
National Cancer Institute
Deadline: June 27, 2011 App July 27, 2011

Supports institutions that serve as accrual groups for  NCI-supported Community Clinical Oncology Program (CCOP) Network.

Patient Advocacy Grant
American Society of Cytopathology Foundation (ASC Foundation)
ASC Foundation Grants
Deadline: App Aug. 15, 2011

For ongoing or new projects for advocacy efforts for patients with gynecologic and other cancers, or for education of the public about the need for effective screening programs.

Investigator Initiated Research Grants
Chordoma Foundation
Deadline: LOI July 15, 2011 App Aug. 15, 2011

Support for investigator-initiated research projects that will advance the development of effective treatments for chordoma.  

Mesothelioma Research Grants
Mesothelioma Applied Research Foundation, Inc. (MARF)
Deadline: App Aug. 5, 2011

For translational research for the treatment of malignant mesothelioma.

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21)
National Cancer Institute (NCI)
Deadline: App June 23, 2011, Nov. 23, 2011

For basic research studies into the causes and mechanisms of cancer health disparities.  

Brian D. Novis Junior Research Grants
International Myeloma Foundation (IMF)
Deadline: App Aug. 1, 2011

To support investigators’ conducting cutting-edge studies to provide better treatment, management, prevention, and ultimately, a cure for myeloma.  

Brian D. Novis Senior Research Grants
International Myeloma Foundation (IMF)
Deadline: App Aug. 1, 2011

Support for doctors and researchers working in the field of myeloma  with a track record in myeloma or related research, for projects which represent a different focus, direction or area of research from those in which they are currently funded.  

Promise Grants
Susan G. Komen for the Cure
Deadline: Proposal July 15, 2011

To support integrated programs of collaborative and cross-disciplinary research projects leading to the accelerated translation of scientific discoveries into interventions and strategies having the greatest potential to significantly reduce breast cancer incidence and mortality.

Clinical Research Professor Award
American Cancer Society (ACS)
Extramural Grants Program
Deadline: LOI Aug. 1, 2011; App Oct. 15, 2011

For established mid-career investigators who have made seminal contributions that have changed the direction of clinical, psychosocial, behavioral, health policy, or epidemiologic cancer research.

Clinical Investigator Award in Breast Cancer Research
Society of Surgical Oncology (SSO)
Deadline: App July 8, 2011

To promote patient-oriented breast cancer research conducted by surgical oncologists in clinical and translational science.

return to top

Published by UIC Cancer Center Communications. Send your news items and events to
CC Update. There is a rolling deadline. You can edit supscription options by emailing listserv@uic.edu with the following words in the body:
"unsubscribe cancercenterres" or "subscribe cancercenterres"